Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Carcinoma, Transitional Cell: full-pipeline trial registry
2 of 6 indexed Carcinoma, Transitional Cell trials are currently recruiting.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Carcinoma, Transitional Cell: 6 US clinical trials tracked, 2 recruiting.
Carcinoma, Transitional Cell is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 2 of these trials.
Enrollment posture brief
Registry condition carcinoma-transitional-cell
OPEN 2 | RECR 33% | LATE 2 | EARLY 3 | RANK #2866 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Carcinoma, Transitional Cell lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Carcinoma, Transitional Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Carcinoma, Transitional Cell is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Carcinoma, Transitional Cell research.
Eli Lilly and Company accounts for 2 of 6 trials (33.3%). 4 distinct sponsors appear on at least one study for this condition label.
-
Typical Carcinoma, Transitional Cell enrolment sits around 348 participants.
Median target enrolment is 348 among the 6 trials that report a genuine target (sentinel values excluded). 2 of those (33.3%) plan for fewer than 100 participants.
-
Carcinoma, Transitional Cell research is mostly interventional.
5 interventional and 1 observational studies make up this index (83.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company
NCT07218380
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
UroGen Pharma
NCT05874921
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Astellas Pharma Global Development
NCT03288545
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Astellas Pharma
NCT03219333
The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study
UroGen Pharma
NCT02793128
Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer
Eli Lilly and Company
NCT00101842
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Carcinoma, Transitional Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Carcinoma, Transitional Cell trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Carcinoma, Transitional Cell page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Carcinoma, Transitional Cell trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Carcinoma, Transitional Cell trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Carcinoma, Transitional Cell condition card totals 6 registered trials; most-linked intervention Platinol; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.